Cyclohexylurea compounds

Details Cyclohexylurea compounds Cyclohexylurea compounds

2005-05-11

2008-03-25

Shameem, Golam M. M. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S469000, C548S494000, C564S305000, C514S415000

Reexamination Certificate

active

07348354

ABSTRACT:
Cyclohexylurea compounds corresponding to formula Ia method for producing them, pharmaceutical compositions containing them, and the use of such compounds as pharmaceutically active agents with nociceptin/ORL1 receptor system activity for treating pain or other conditions associated with the nociceptin/ORL1 receptor system.

REFERENCES:
patent: 7173045 (2007-02-01), Sundermann et al.
patent: 392498 (1965-05-01), None
patent: 19756036 (1999-06-01), None
patent: 69515465 (2000-08-01), None
patent: WO 01/83452 (2001-11-01), None
patent: WO 01/87838 (2001-11-01), None
patent: WO 02/055521 (2002-07-01), None
Faud A. Abdulla et al., “Axotomy Reduces the Effect of Analgesic Opioids Yet Increases the Effect of Nociceptin on Dorsal Root Ganglion Neurons,” The Journal of Neuroscience, Dec. 1, 1998, pp. 9685-9694, 18, 23, Society for Neuroscience.
Girolamo Calo et al., “Pharmacology of Nociceptin and its Receptor: A Novel Therapeutic Target,” British Journal of Pharmacology, 2000, pp. 1261-1283, 129, Macmillan Publishers Ltd.
Francois Jenck et al., “Orphanin FQ Acts as an Anxiolytic to Attenuate Behavioral Responses to Stress,” Proc. Natl. Acad. Sci., Dec. 1997, pp. 14854-14858, vol. 94, USA.
Michael A. King et al., “Spinal Analgesic Activity of Orphanin FQ/Nociceptin and its Fragments”, Neuroscience Letters, 1997, pp. 113-116, 223, Elsevier Science Ireland Ltd.
Toshiya Manabe et al., “Facilitation of Long-Term Potentiation and Memory in Mice Lacking Nociceptin Receptors”, Letters To Nature, Aug. 6, 1998, pp. 577-581, vol. 394, Macmillan Publishers Ltd.
Jean-Claude Meunier et al., “Isolation and Structure of the Endogenous Agonist of Opiod Receptor-Like ORL, Receptor,” Letters to Nature, Oct. 12, 1995, pp. 532-535, vol. 377.
J.S. Mogil et al., “Orphanin FQ is a Functional Anti-Opioid Peptide”, Neuroscience, 1996, pp. 333-337, vol. 75, No. 2, Elsevier Science Ltd., Great Britain.
Miyuki Nishi et al., “Unrestrained Nociceptive Response and DIsregulation of Hearing Ability in Mice Lacking the Nociceptin/OrphaninFQ Receptor,” The EMBO Journal, 1997, pp. 1858-1864, vol. 16, No. 8, Oxford University Press.
Rainer K. Reinscheid et al., “Orphanin FQ: A Neuropeptide That Activates an Opioldlike G Protein-Coupled Receptor,” Science, Nov. 3, 1995, pp. 792-794, vol. 270.
Daniel Lednicer et al., “4-Amino-4-arylcyclohexanones and Their Derivatives, a Novel Class of Analgestics”, J. Med. Chem., 1980, pp. 424-430, 23.

Affiliated with

Also associated with

Rating

Cyclohexylurea compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclohexylurea compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclohexylurea compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3969314